Trodelvy (sacituzumab govitecan-hziy) vs Orserdu (elacestrant)
Trodelvy (sacituzumab govitecan-hziy) vs Orserdu (elacestrant)
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate specifically indicated for the treatment of metastatic triple-negative breast cancer and has shown effectiveness in patients who have received two or more prior systemic therapies. On the other hand, Orserdu (elacestrant) is a selective estrogen receptor degrader (SERD) that is used for the treatment of ER+/HER2- advanced or metastatic breast cancer in postmenopausal women or adult men who have progressed on or after an endocrine-based therapy. The choice between Trodelvy and Orserdu would depend on the specific breast cancer subtype, hormone receptor status, prior treatments, and the individual patient's health profile, which should be evaluated by a healthcare professional.
Difference between Trodelvy and Orserdu
Metric | Trodelvy (sacituzumab govitecan-hziy) | Orserdu (elacestrant) |
---|---|---|
Generic name | Sacituzumab govitecan-hziy | Elacestrant |
Indications | Metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, at least one of them for metastatic disease. | Advanced or metastatic ER+/HER2- breast cancer with ESR1 mutation in postmenopausal women or adult men after progression on endocrine therapy. |
Mechanism of action | Antibody-drug conjugate targeting Trop-2; delivers the cytotoxic drug SN-38. | Oral selective estrogen receptor degrader (SERD). |
Brand names | Trodelvy | Orserdu |
Administrative route | Intravenous | Oral |
Side effects | Neutropenia, diarrhea, nausea, fatigue, anemia, vomiting, alopecia, constipation, decreased appetite, rash, and abdominal pain. | Not fully characterized but may include nausea, vomiting, fatigue, decreased appetite, and musculoskeletal pain. |
Contraindications | Severe hypersensitivity to sacituzumab govitecan-hziy or its excipients. | Not fully characterized but may include severe hypersensitivity to elacestrant or its excipients. |
Drug class | Antibody-drug conjugate | Selective estrogen receptor degrader (SERD) |
Manufacturer | Gilead Sciences, Inc. | Radiopharm Theranostics |
Efficacy
Trodelvy (sacituzumab govitecan-hziy) Efficacy in Breast Cancer
Trodelvy (sacituzumab govitecan-hziy) is an antibody-drug conjugate specifically indicated for the treatment of adult patients with metastatic triple-negative breast cancer (TNBC) who have received at least two prior therapies for metastatic disease. The efficacy of Trodelvy in this patient population was demonstrated in a study that showed a significant improvement in overall survival and progression-free survival when compared to chemotherapy. Patients treated with Trodelvy had a median overall survival of 12.1 months compared to 6.7 months in those receiving standard chemotherapy. Furthermore, the progression-free survival was also extended with Trodelvy, indicating its effectiveness in delaying disease progression in patients with metastatic TNBC.
Orserdu (elacestrant) Efficacy in Breast Cancer
Orserdu (elacestrant) is a selective estrogen receptor degrader (SERD) that is used in the treatment of estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This medication is particularly utilized in cases where the cancer has progressed following endocrine therapy. Clinical trials have shown that Orserdu can reduce the risk of disease progression or death in patients with this subtype of breast cancer. In a pivotal trial, patients treated with Orserdu demonstrated a median progression-free survival that was notably longer than those who received standard endocrine therapy, indicating its potential as an effective treatment option for ER-positive, HER2-negative breast cancer.
Both Trodelvy and Orserdu represent significant advancements in the treatment of breast cancer, addressing different subtypes of the disease with targeted mechanisms of action. While Trodelvy targets the TNBC population, Orserdu offers a new line of therapy for patients with ER-positive, HER2-negative breast cancer. The efficacy of these drugs in improving survival outcomes underscores their importance in the management of breast cancer and provides new hope for patients with advanced disease.
It is important to note that the efficacy of these medications can vary based on individual patient factors, prior treatments, and the specific characteristics of the breast cancer. Healthcare providers consider these factors when determining the appropriateness of Trodelvy or Orserdu for their patients. Ongoing research and clinical trials continue to refine the understanding of these drugs' efficacy and their role in the broader landscape of breast cancer treatment.
Regulatory Agency Approvals
Trodelvy
Orserdu
Access Trodelvy or Orserdu today
If Trodelvy or Orserdu are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us